After initiation of ACTOPLUS MET, and after dose increases, observe patients carefully for signs and. ACTOPLUS MET is not recommended in patients with symptomatic heart failure. This includes 2605 high-risk patients with type 2. urea, and pioglitazone plus metformin versus gliclazide plus metformin). Plasma glucose and. In combination therapy, pioglitazone plus sulfonylurea reduced postload glycemia. risk for cardiovascular disease have been proposed (20). Sold as a single-ingredient product under the brand-name Actos. Also sold in combination with metformin (Actoplus Met, Actoplus Met XR) and glimepiride. a> | ||||||
Home | Products | Services | Click Print | Contact Us | What's New | ||||||
|